Qualigen Therapeutics (NASDAQ:AIXC) Posts Earnings Results

Qualigen Therapeutics (NASDAQ:AIXC) issued its quarterly earnings results on Tuesday. The company reported ($0.79) earnings per share for the quarter, FiscalAI reports.

Qualigen Therapeutics Price Performance

Qualigen Therapeutics stock traded down $0.02 during midday trading on Wednesday, reaching $1.29. The stock had a trading volume of 23,849 shares, compared to its average volume of 63,890. The firm has a market cap of $26.01 million, a price-to-earnings ratio of -0.17 and a beta of 0.52. Qualigen Therapeutics has a 12 month low of $0.92 and a 12 month high of $8.81. The business has a 50-day moving average of $1.30.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Qualigen Therapeutics in a research report on Friday, April 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.